A recent study published in MedComm – Future Medicine by a research team from Fudan University provides an in-depth ...

“Patients with grade two glioma who had IDH1 mutation treated with Vorasidenib doubled in terms of survival. And it’s a ...

Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...

Firefighters show higher rates of glioma-linked SBS42 mutational signatures associated with haloalkane exposure, suggesting ...

A similar effort would be welcomed in lower grade gliomas, particularly those with IDH1/IDH2mutation and 1p/19q codeletion, more vulnerable to treatment and therefore representing some kind of ...

New research by Yale has found an association between exposure to chemicals commonly used in firefighting and incidence of a ...

The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by ...

Published recently in the journal Frontiers in Nutrition, the report is the first evaluation of the use of ketogenic metabolic therapy (KMT) without chemo or radiation interventions, on a patient ...

UCLA co-led study is first trial analyzing a targeted therapy drug specifically made for brain tumors. In an international study co-led by UCLA Health Jonsson Comprehensive Cancer Center ...

Malignant gliomas and medulloblastomas — the most common brain tumours affecting adults and children, respectively — remain responsible for a disproportionate level of morbidity and mortality ...